Bradley Merrill Thompson, Strategic Advisor with EBG Advisors and Member of the Firm at Epstein Becker Green, speaks on "Legal and Regulatory Opportunities to Address Bias and Transparency in Artificial Intelligence/Machine Learning (AI/ML) in Medical Devices," at the Food and Drug Law Institute (FDLI) Annual Conference: Exploring Advanced Topics in Food and Drug Law.
Al/ML-based technologies have the potential to transform health care through their unique ability to learn from real-world feedback and adapt based on these learnings. However, the data that is used to learn may drive inherent biases. What can FDA and companies do to ensure that AI/ML-enabled products do not reproduce or amplify existing inequalities? Brad and others explore how biases from collection can degrade AI/ML algorithm performance and what tools FDA and companies can use to help combat bias.
For more information and to register, please visit FDLI.org.